Clostridium difficile infection in an Iranian hospital

BMC Research Notes

J Scott Weese¹  Keith Warriner⁴  Farzin Khorvash²  Mohammad Jalali³ 

[1] Department of Pathobiology, University of Guelph, Guelph, ON, N1G 2W1, Canada;Department of Infectious Disease, Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran;School of Nutrition and Food Sciences and Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran;Department of Food Sciences, University of Guelph, Guelph, ON, Canada

关键词: Gastroenterology;    Infectious disease;    Nosocomial;    Diarrhea;    Clostridium difficile;   

Others  :  1166560
DOI  :  10.1186/1756-0500-5-159

 received in 2011-09-15, accepted in 2012-03-21,  发布年份 2012

【 摘 要 】

Background

Clostridium difficile infection (CDI) is an important cause of morbidity and mortality internationally, yet there are important regional differences in the epidemiology and microbiology of disease. Most reports have come from North America and Europe, with limited information from other regions, including the Middle East. Given the changes in the epidemiology of CDI in developed countries, particularly associated with the dissemination of hypervirulent epidemic clones, an understanding of the epidemiology and microbiology of CDI in diverse regions is warranted. This study involved collection of stool samples from individuals with diarrhea at the Isfahan University of Medical Sciences Teaching Hospital, Isfahan, Iran, between October 2010 and March 2011. Selective enrichment culture for C. difficile was performed and isolates were characterised using ribotyping, PCR for the detection of tcdA, tcdB and cdtB genes, and tcdC sequence analysis.

Findings

Clostridium difficile was isolated from 19/89 (21%) stool samples of 17/86 (20%) patients. 13/17 (77%) cases of CDI were hospital-associated. Patients with CDI were significantly older (43 ± 28y) than those with non-CDI diarrhea (24, ± 26y)(P = 0.018). All isolates were toxigenic, and possessed genes encoding for toxins A and B. Six (32%) of 19 isolates also possessed cdtB. Twelve ribotypes were identified. Ribotype 078/toxinotype V was most common, accounting for 4 (21%) of isolates. A single isolate of a different toxinotype V ribotype was identified, as was a toxinotype XXIV isolate. The remaining isolates consisted of 9 different toxinotype 0 ribotypes.

Conclusions

CDI is an important cause of diarrhea in patients in this hospital. The diversity of ribotypes was striking, and the number of different types suggests the presence of a broad range of strains in the community, the hospital or both. The predominance of toxinotype V strains, which have been associated with community-associated disease and food animals, was unexpected and possible sources of this type require further investigation.

【 授权许可】

   
2012 Jalali et al.; licensee BioMed Central Ltd

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Pépin J, Valiquette L, Alary M, Villemure P, Pelletier A, Forget K, Pépin K, Chouinard D: Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004, 171(5):466-472.
• [2]Centers for Disease Control and Prevention: Severe Clostridium difficile-associated disease in populations previously at low risk–four states, 2005. MMWR Morb Mortal Wkly Rep 2005, 54(47):1201-1205.
• [3]Goorhuis A, Van der Kooi T, Vaessen N, Dekker F, Van den Berg R, Harmanus C, van den Hof S, Notermans D, Kuijper E: Spread and epidemiology of Clostridium difficile polymerase chain reaction ribotype 027/toxinotype III in The Netherlands. Clin Infect Dis 2007, 45(6):695-703.
• [4]Mulvey MR, Boyd DA, Gravel D, Hutchinson J, Kelly S, Mcgeer A, Moore D, Simor A, Suh KN, Taylor G, Weese JS, Miller M: Hypervirulent Clostridium difficile strains in hospitalized patients. Canada. Emerging Infect Dis 2010, 16(4):678-81.
• [5]Rupnik M, Widmer A, Zimmermann O, Eckert C, Barbut F: Clostridium difficile toxinotype V, ribotype 078, in animals and humans. J Clin Microbiol 2008, 46:2146.
• [6]McDonald L, Coignard B, Dubberke E, Song X, Horan T, Kutty P: Unknown: Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2007, 28(2):140-145.
• [7]Kato H, Kato N, Watanabe K, Iwai N, Nakamura H, Yamamoto T, Suzuki K, Kim S, Chong Y, Wasito E: Identification of toxin A-negative, toxin B-positive Clostridium difficile by PCR. J Clin Microbiol 1998, 36(8):2178-2182.
• [8]Stubbs S, Rupnik M, Gibert M, Brazier J, Duerden B, Popoff M: Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol Lett 2000, 186(2):307-312.
• [9]Lemee L, Dhalluin A, Testelin S, Mattrat M, Maillard K, Lemeland J, Pons J: Multiplex PCR targeting tpi (triose phosphate isomerase), tcdA (Toxin A), and tcdB (Toxin B) genes for toxigenic culture of Clostridium difficile. J Clin Microbiol 2004, 42(12):5710-5714.
• [10]Bidet P, Barbut F, Lalande V, Burghoffer B, Petit J: Development of a new PCR-ribotyping method for Clostridium difficile based on ribosomal RNA gene sequencing. FEMS Microbiol Lett 1999, 175(2):261-266.
• [11]Rupnik M, Avesani V, Janc M, von Eichel-Streiber C, Delmée M: A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J Clin Microbiol 1998, 36(8):2240-2247.
• [12]Curry SR, Marsh JW, Muto CA, O’Leary MM, Pasculle AW, Harrison LH: tcdC genotypes associated with severe TcdC truncation in an epidemic clone and other strains of Clostridium difficile. J Clin Microbiol 2007, 45(1):215-221.
• [13]Sadeghifard N, Salari MH, Ghassemi MR, Eshraghi S, Amin Harati F: The incidence of nosocomial toxigenic Clostridium difficile associated diarrhea in Tehran tertiary medical centers. Acta Med Iran 2010, 48(5):320-325.
• [14]Sadeghifard N, Salari MH, Ranjbar R, Ghafouryan S, Raftari M, Abdulamir AS, Fatimah AB, Kazemi B: The clinical and environmental spread and diversity of toxigenic Clostridium difficile diarrheic in the region of the Middle East. Rev Infection 2010, 1:180-187.
• [15]Al-Tawfiq JA, Abed MS: Clostridium difficile-associated disease among patients in Dhahran, Saudi Arabia. Travel Med Infect Dis 2010, 8(6):373-376.
• [16]Jamal W, Rotimi VO, Brazier J, Duerden BI: Analysis of prevalence, risk factors and molecular epidemiology of Clostridium difficile infection in Kuwait over a 3-year period. Anaerobe 2010, 16(6):560-565.
• [17]Nasereddin LM, Bakri FG, Shehabi AA: Clostridium difficile infections among Jordanian adult hospitalized patients. Am J Infection Control 2009, 37(10):864-866.
• [18]Barbut F, Corthier G, Charpak Y, Cerf M, Monteil H, Fosse T, Trévoux A, De Barbeyrac B, Boussougant Y, Tigaud S, et al.: Prevalence and pathogenicity of Clostridium difficile in hospitalized patients. A French multicenter study. Arch Intern Med 1996, 156(13):1449-1454.
• [19]Goorhuis A, Bakker D, Corver J, Debast SB, Harmanus C, Notermans DW, Bergwerff AA, Dekker FW, Kuijper EJ: Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 2008, 47(9):1162-1170.
• [20]Centers for Disease Control and Prevention (CDC): Surveillance for community-associated Clostridium difficile--Connecticut, 2006. MMWR Morb Mortal Wkly Rep 2008, 57(13):340-343.
• [21]Vindigni SM, Shane AL: Clostridium difficile infections among hospitalized children, United States, 1997–2006. Emerging Infect Dis 2010, 16(10):1651-1652.
• [22]Paltansing S, van den Berg RJ, Guseinova RA, Visser CE, van der Vorm ER, Kuijper EJ: Characteristics and incidence of Clostridium difficile-associated disease in The Netherlands, 2005. Clin Microbiol Infect 2007, 13(11):1058-1064.
• [23]Jamal WY, Rotimi VO, Grubesic A, Rupnik M, Brazier JS, Duerden BI: Correlation of multidrug resistance, toxinotypes and PCR ribotypes in Clostridium difficile isolates from Kuwait. J Chemother 2009, 21(5):521-526.
• [24]Rotimi VO, Jamal WY, Mokaddas EM, Brazier JS, Johny M, Duerden BI: Prevalent PCR ribotypes of clinical and environmental strains of Clostridium difficile isolated from intensive-therapy unit patients in Kuwait. J Med Microbiol 2003, 52(Pt 8):705-709.
• [25]Jhung M, Thompson A, Killgore G, Zukowski W, Songer G, Warny M, Johnson S, Gerding D, McDonald L, Limbago B: Toxinotype V Clostridium difficile in Humans and Food Animals. Emerging Infect Dis 2008, 14(7):1039-1045.
• [26]de Boer E, Zwartkruis-Nahuis A, Heuvelink AE, Harmanus C, Kuijper EJ: Prevalence of Clostridium difficile in retailed meat in the Netherlands. Int J Food Microbiol 2011, 144(3):561-564.
• [27]Songer JG, Trinh HT, Killgore GE, Thompson AD, McDonald LC, Limbago BM: Clostridium difficile in retail meat products, USA, 2007. Emerging Infect Dis 2009, 15(5):819-821.
• [28]Weese JS, Avery BP, Rousseau J, Reid-Smith R: Detection and enumeration of Clostridium difficile in retail beef and pork. Appl Environ Microbiol 2009, 75(15):5009-5011.
• [29]Rupnik M: Is Clostridium difficile-associated infection a potentially zoonotic and foodborne disease? Clin Microbiol Infect 2007, 13(5):457-459.
• [30]McDonald L, Killgore G, Thompson A, Owens R, Kazakova S, Sambol S, Johnson S, Gerding D: An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005, 353(23):2433-2441.